Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2006

View Archived Issues

Tolevamer effective in Clostridium difficile-associated diarrhea

Malaria vaccine RTS,S/AS02A safe, immunogenic in East African population

CytoDyn acquires Advanced Influenza Technologies

Pollinex Quattro Grass development discussed with Japanese PMDA

Immunosuppressive agents in preclinical and clinical studies: Snapshots

Studies detail preclinical activity and pharmacokinetics of NVP-AEB-071

CP-690550 pharmacokinetics and safety assessed in renal transplant patients

Cubist evaluates strategic options for HepeX-B

New antimalarial CDA studied in sub-Saharan Africa

beta-Synuclein peptides highlighted as novel treatment options for AD

CTCE-0324 demonstrates blood vessel regeneration effects

Ethics approvals for phase II study of Coramsine in renal cell carcinoma

Study of VGV-1 shows HIV viral load reductions

Termination of TROICA study of Metalyse in out-of-hospital cardiac arrest

Phase II protocol filed for Davanat in first-line colorectal cancer

PreHistin begins twin phase III allergy trials

Org-36286 enters phase III in treatment of infertility

Phase I/II asthma study completes for intravenous zileuton

New River exercises copromotion option for NRP-104

GSK's H5N1 flu vaccine achieves high immune response at low antigen dose

Atacicept demonstrates good tolerability and biologic activity in SLE patients

NGX-267 shows evidence of cholinergic activation in elderly subjects

Two Alcon ophthalmic drugs receive Japanese approval

Recent patents impart new therapeutic agents for cancer

Novel prostanoid EP2 agonists for glaucoma emerge from Allergan

New agents reported for thrombotic disorders and associated complications

Negamycin and its analogues in Duchenne's muscular dystrophy

Japanese approval for Baraclude

Oral antifungal Itrizole approved in Japan

Once-weekly alendronate sodium hydrate products approved in Japan

Japanese approval for Pulmicort for asthma in infants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...